We report an improved "high-performance" liquid-chromatographic (HPLC) method for measuring biopterin and neoptenn in serum and urine. Specimens are acidified, treated with iodine in 0.2 mol/L trichloroacetic acid, partly purified on Bio-Rad MP-50 cation-exchange columns, and analyzed by reversed-phase HPLC with fluorometnc detection. The minimal concentration of bioptenn detectable is 0.3 g/L in a 50-L injection. The total CV is i 0%. Improvements over other reported methods include the use of a single, simplified sample-preparation step with a Baker-i 0 SPE System, and a guard column to increase analytical column stability and analyte recovery. The assay is semiautomated to reduce technician time and improve precision. Mean observed values for bioptenn and neopterin in sera of normal human adults were 1.64 and 5.52 1zg/L, respectively. The mean ratio of neopterin to biopterin in acidified adult urine samples was lower than that found in matched nonacidified samples (n = 10). Serum specimens from diagnosed phenylketonuric (PKU) and hyperphenylalaninemic patients were also analyzed for biopterin and neopterin; the findings agreed with reported values for similar patients. One patient, previously identified as an atypical PKU patient, showed serum values of neoptenn and biopertin suggestive of a defect in bioptenn synthesis. for detecting biopterin and other pteridines that enabled quantification at picomole quantities.
course of treatment that only in part parallels conventional PKU therapy. Thus, special diagnostic methods are required to differentiate biopterin-related defects from classic PKU and hydroxylase-associated hyperphenylala-
ninemias.
Neopterin is an important intermediate in the de 'woo synthesis of biopterin from guanosine triphosphate (3) (4) (5) (6) .
The synthesis block that causes biopterin deficiency can occur after the formation of neopterin, causing abnormally high concentrations of this pteridine (7). More recently, deficiency of GTP cyclohydrolase I (EC 3.5.4. 16) , in which the conversion of GTP to D-eiythro-dihydroneopterin tnphosphate is blocked, has been reported (8, 9) .
The differential diagnosis of cofactor-related hyperphenylalaninemias depends on the following observations. An above-normal concentration of total biopterin with normal or slightly increased neopterin concentrations is associated with deficiency of DHPR. An increased neopterin/biopterin ratio (increased neopterin and decreased biopterin concentrations) suggests a block in the synthesis of BH4. GTP cyclohydrolase I deficiency is characterized by extremely low concentrations of both neopterin and biopterin (10) . for detecting biopterin and other pteridines that enabled quantification at picomole quantities.
They measured alkaline-stable biopterin after oxidizing the specimen by addition of an alkaline iodine solution. Total biopterin, reduced and oxidized, was then measur after oxidizing the specimen with an acidic solution. Salts, nonspecific fluorescent compounds, and high-molecular mass molecules that would interfere with the separatio and detection of the analytes were removed by passag through a Dowex 50 column and then through a Dowex column. After these purification steps, the eluates we subjected to HPLC analysis with fluorometric detection Neopterin was also measured with this method. This an other reported methods are lengthy and tedious; specime throughput is slow (16, 17) . We report an improved method that requires smalle volumes of serum or urine and apply it to the measuremen of biopterin and neopterin in normal volunteers and i patients diagnosed as hyperphenylalaninemic.
Materials and Methods
Aqueous biopterin and neopterin standards. We dissolv 10 mg of crystalline biopterin (Calbiochem, La Jolla, CA) in 800 mL of de-ionized distilled water, by gently heatin and stirring it constantly and then cooling it slowly to roo temperature. The solution was diluted to 1 L with deionized distilled water and stored at 4 #{176}C for further use. Crystalline neopterin (the kind gift of Dr. Edwin W. Naylor of Western Pennsylvania Hospital) was processed in the same manner.
Reduced biopterin standards.
We synthesized BH4 and dihydrobiopterin (BH2) as described by Kaufman (18) , using a Supelco Micro-hydrogenator (Supelco, Inc., Bellefonte, PA) for the BH4 reaction. The products were placed in screw-cap amber vials, flooded with N2, and stored at -40 #{176}C. We determined the identity and purity of the products as described by Kaufman (18) .
Pteridine -deficient serum.
Fresh-frozen serum from adults was thawed at 4#{176}C and centrifuged at 3000 x g for 30 mm at 4 #{176}C. The supernate was filtered sequentially through 0.45-and 0.20-sm (pore size) Millipore filters in Nalgene sterilization filtration units. We dialyzed the final filtrate for 48 h against the following buffer (per liter): 0.02 mol of Tris -HC1, 0.15 mol of NaC1, and 0.2 g of NaN3. The bufferwas adjusted to pH 8.0, de-aerated, and bubbled with N2. About 400 mL of the serum filtrate was dialyzed in 4 L of buffer with constant slow stirring, and the starting buffer was decanted and replaced with fresh buffer after 24 h. We monitored the removal of pteridines by HPLC. Dilutions of the aqueous stock standards were added to dialyzed serum to prepare serum-based assay calibrators and quality-control (QC) materials containing various concentrations of biopterin and neopterin.
BH4 and BH2 serum calibrators were prepared as needed.
Specimen collection. Venous blood specimens were drawn and allowed to clot in the dark at room temperature for 10-15 mm. After clotting, the sample was centrifuged and the supernatant serum frozen at -40 #{176}C. Plasma specimens, collected into heparinized tubes, were treated in the same manner as serum specimens. Clean-catch urine specmiens were collected from 10 apparently healthy adult volunteers at the time of serum collection and frozen without delay at -40 #{176}C. To evaluate urine collection methods, a 5-mL portion of each freshly collected specimen was acidified with 0.1 mL of 4 mol/L HC1 and stored at -40 #{176}C. All urine samples were diluted 500-fold in deionized distilled water for analysis.
Two milliliters of diluted sample was required for each analysis. The human serum and urine specimens from healthy adults were assayed for biopterin and neopterin by the HPLC assay method, as were seven blind-coded serum or plasma specimens from PKU-affected patients (ranging in age from five weeks to 25 years), obtained from Dr. Harvey (per milliliter). HPLC system. We used the Series 7800 modular HPLC system from Laboratory Data Control (LDC, Division of Milton Roy, Riviera Beach, FL), which included two Constametric ifi mobile-phase pumps, a Rheodyne injector, a Fluoromonitor Ill fluorometer, a two-channel printer/ploter, and a Chromatographic Control Module minicomputer. An autosampler with a Rheodyne injector was also inluded in the system. The continuous-flow fluorometer was uipped with a 360-nm black fluorescent excitation lamp, a 370-nm excitation filter, and a 418-700-nm emission filter. We used 250 x 4.6 mm Excalibur 5-sm octadecylsilane (ODS) reversed-phase columns (Applied Science Division, Milton Roy Co., State College, PA) for pteridine analysis. A 70 x 4.6 mm guard column, to protect the analytical column from contamination by impurities in the processed specimen, was made by slurry-packing the short column with a methanol suspension of 5-sm spherisorb ODS (Applied Science Division, Milton Roy Co.).
Ion-exchange chromatography.
Small (column bed = 5 X 10 mm) ion-exchange columns (1-mL syringe barrels) were packed with a loose, aqueous slurry of Bio-Rad AGMP-50, 200-400 mesh (H) cation-exchange resin (Bio-Rad, Richmond, CA). We processed 10 columns at a time with a Baker-lO SPE apparatus (J.T. Baker Chemical Co., Phillipsburg, NJ 08865) to partially purify oxidized specimens before HPLC analysis. We also prepared anion-exchange columns, as described by Fukushima and Nixon (16) , in an attempt to further purify and concentrate serum samples. Experimental protocol. Calibrators containing neopterin and bioptermn (1-5 igfL each) and biopterin QC materials (0.5, 1.5, 3.5, and 4.5 g/L) were analyzed in duplicate, along with single 2-mL aliquots of each thawed specimen (serum or urine). We added 0.5 mL of 300 g/L trichloroacetic acid reagent and 0.25 mL of iodine solution (5 g of 12 and 10 g of KI in 0.2 mol/L trichloroacetic acid solution) to each tube, mixed the samples thoroughly, and incubated them for 1.0 hat room temperature under reduced light. We then centrifuged the samples at 3100 x g for 30 mm at 4#{176}C. We used an Eppendorf pipette to transfer 1.75 mL of supernate to separate, disposable cation-exchange columns. After attaching the system to reduced pressure, we washed each column with 5 mL of de-ionized distilled water, positioned collection vials in the extraction system, and eluted the biopterin and neopterin with 2 mL of 1 mol/L NH4OH reagent. We added 30 L of glacial acetic acid to each collection vial to neutralize the eluate. The tubes were capped and vigorously vortex-mixed for 2-3 s. We analyzed the neutralized eluate by HPLC with the following chromatographic conditions: mobile phase, methanol and water (15/ 
Results

Chromatograms
of the analysis of paired acidified/nonacidified urine samples from split specimens and of the corresponding serum specimens are shown in Figure 1 . Detection limits for the assay (the apparent concentrations 3 SD from the minimal measurable concentrations of biopterin and neopterin) were <0.3 g/L each in a 50-jL sample injection. Fluorescence peak height was proportional to the concentration of pteridine present (r2 >0.9988, y-intercept not significantly different from zero). We determined the analytical recovery for the assay by diluting stock solutions of aqueous biopterin from 100 to 5 g/L in distilled water and in pteridine-free pooled serum. Two-milliliter portions of fortified serum were assayed in 10 independent runs; 10 samples of the aqueous biopterin solution were injected directly onto the analytical column. Peak heights for biopterin were recorded and serum values were adjusted for dilution during the assay procedure. Based on peak-height measurements, the percent of added biopterin recovered from the sera pool was 99%. This compared favorably with the mean percent recovery of 103% observed for the QC materials. The analytical recoveries of biopterin for QC materials 1-4 were 116%, 102%, 97%, and 100%, respectively ( Table 1 ). mean values obtained for the QC materials are within 3% ol expected recovery values at all four concentrations. Table 2 presents the findings in biopterin and neopterin assays of serum specimens obtained from 10 healthy adult volunteers.Urine specimens collected at the time of serum collection from the same volunteers were also analyzed (Table 3) . We split each urine specimen, acidified one portion, and left the remainder untreated.
HPLC assay results showed the biopterin and neopterin concentrations were 200 to 600 times greater in urine than in serum. Acidifying the urine caused an 18% decrease in measured biopterin concentration and a 41% decrease in measured neopterin concentrations.
This effect was consistent from specimen to specimen. In a linear-regression analysis of acidified vs nonacidifled assay values, r2 was 0.993 for biopterin and 0.997 for neopterin. For all 10 urine specimens, acidification caused a significant decrease in measured pteridine (Student's t-test, P <0.01). for mean values of biopterin and neopterin, measured from both acidified and nonacidifled urine specimens, were reduced from about 90% to <26% (n = 10). Pteridine concentrations and creatimne content are strongly correlated; the coefficients of determination were 0.939 and 0.858 for biopterin and neopterin, respectively.
In Table 4 we show assay results of serum specimen from six patients diagnosed for PKU and one patien suspected of having tyrosinosis. Except for one patien diagnosed as an abnormal phenylketonuric and the patien with increased tyrosine, all patients had increased Ph Table 2 , all but one of the PKU patients hai increased biopterin concentrations, normal neopterin con centrations, and depressed neopterin-to-biopterin ratios. Ratio of neopterin to bloptefln.
concentrations(i.e., >40 mg/L). When compared with th data in
Discussion
We used specially prepared, disposable cation-exchange columns with the Baker-lO SPE system for sample preparation and a short guard column with a reversed-phase analytical column in an HPLC method with fewer intermediate preparation steps and significantly improved effective column life. We improved sample preparation by using a single extraction step with small, easily prepared columns packed with Bio-Rad AGMP cation-exchange resin. Subsequent extraction steps with fragile, anion-exchange columns to further concentrate and (or) purify specimens (as described by others) were not necessary for this method. Eluates were collected directly into small storage vials with no transfer step. Both biopterin and neopterin were quantitatively measured in both serum and urine with excellent analytical recovery (>98%).
Parallel alkaline oxidation of prepared serum pools did not yield satisfactory recovery of reduced forms of biopterin as fully oxidized, fluorescent biopterin. In fact, whereas about 80% less BH4 was recovered as fully oxidized bioptern by alkaline oxidation than by acid oxidation, in agreement with Fukushima and Nixon (16) , only about 42% of BH2 was recovered as biopterin when oxidized under alkaline conditions. Similar recoveries were demonstrated for neopterin. As a result of these findings, only an acid-oxidation step was used to measure biopterin content. Spherisorb ODS analytical columns, which gave satisfactory resolution of all pteridmnes tested, initially gave erratic results for processed serum and urine samples. This was attributed to slight pH differences in the neutralized eluates and, as a result, limited the number of effective runs to Less than ten. 
sam-
ples on the analytical column were eliminated, and up to 200 successive injections without column regeneration were possible with a 2-mm wash of standard mobile phase after each run. As a result, the pH balance of the final extraction eluates was not as critical: a simple, isocratic mobile phase could be used; and injection of samples and calibrators was easily automated.
All specimens were frozen (-40 #{176}C) after collection; the effect of acidification of urine specimens, as recommended by some (21, 22) , was examined. To normalize urine values for each analyte, we also made creatinine measurements (23) . These correlated well with biopterin and neopterin values. We found that the creatinine-adjusted neopterinto-biopterin ratio of the acidified urine samples (0.80) varied significantly from that of the nonacidified samples (1.14) atP = 0.01. Assayed measurements of biopterin and neopterin in acidified urine sampleswere generally lower than those of nonacidifled samples. It is difficult to evaluate the practical effects of specimen acidification on analytical results as reported by others (21,22,24,25) .
Age pairing or other matching approaches of results may be important in establishing normal values of measured pteridines (22,24). We also found that serum and urine values of biopterin and neopterin for paired specimens from normal individuals were not strongly correlated (for biopterin, r2 values were 0.058 and 0.146 for nonacidified and acidified urine specimens, respectively).
These observations suggest that specimen selection, collection, and handling before analysis are critical in establishing normal values and making clinical assessments in pteridine-associated disorders. Using the reported method, we assayed serum or plasma specimens from six patients with hyperphenylalaninemia and one with tyrosinemia.
The results for biopterin and neopterin are slightly lower than those from similar subjects reported elsewhere (22, 24) , perhaps because of relative assay specificity. However, the neopterin-to-biopterin ratios reported here are in close agreement with those previously reported (22, 24) . This supports using the ratio of these analytes in the diagnosis and characterization of cofactor-related hyperphenylalaninemias and perhaps other disorders marked by abnormal concentrations of these pteridines (12, 26, 27) .
The measurement of biopterin and neopterin in serum and urine specimens is an accepted approach in the detection and evaluation of hyperphenylalarnnemia and other disorders.
The reported method uses simplified sample preparation steps to measure biopterin and neopterin and is easily automated for unattended operation. Reliable analyticalresults confirm the identification of a hyperphenylalaninemic variant.
Reproducibility of results and highvolume specimen-throughput capacity easily permit the differentiation of various pteridine-associated disorders and the determination of normal reference ranges for biopterin and neopterin values.
